Celcuity (CELC) Stock Forecast & Price Target

Celcuity is a clinical-stage biotechnology company focused on the development of targeted therapies for multiple solid tumors, with a primary focus on HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer. They have a strong pipeline of clinical trials for their lead candidate gedatolisib, which has shown promising results in Phase 3 trials and could potentially become a first-in-class treatment option for patients with HR+/HER2- breast cancer. While there are typical risks for a development stage biotechnology company, we expect the positive results from their ongoing trials and differentiated mechanism of action to drive potential upside for the company's future success.

Celcuity is a clinical-stage biotech company with a lead candidate, gedatolisib, in late-stage development for multiple cancers. Although the company has ongoing trials, the PI3K/AKT/mTOR mechanism is not unique, competition is intense, and there is a risk of not obtaining commercial success. The possibility for a positive catalyst at the 2026 ASCO conference and potential FDA approval for PIK3CA mutations could result in a peak market penetration of 20%, but we assign a 60% likelihood for a base case with a $165 price target and move to a Buy rating.